Search results
Showing 1201 to 1250 of 2065 results for work
In development Reference number: GID-TA11808 Expected publication date: TBC
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .
In development Reference number: GID-TA11365 Expected publication date: TBC
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]
In development Reference number: GID-TA11344 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113
In development Reference number: GID-TA11025 Expected publication date: TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Discontinued Reference number: GID-TA10019
In development Reference number: GID-TA11001 Expected publication date: TBC
In development Reference number: GID-TA11582 Expected publication date: TBC
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Discontinued Reference number: GID-TA10722
In development Reference number: GID-TA11586 Expected publication date: TBC
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
In development Reference number: GID-TA11366 Expected publication date: TBC
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]
Discontinued Reference number: GID-TAG431
Discontinued Reference number: GID-TAG456
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Discontinued Reference number: GID-TA10234
Discontinued Reference number: GID-TA10390
In development Reference number: GID-TA10667 Expected publication date: TBC
Clostridium difficile associated diarrhoea - tolevamer [ID378]
Discontinued Reference number: GID-TAG389
In development Reference number: GID-TA11486 Expected publication date: TBC
Discontinued Reference number: GID-TA10018
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development Reference number: GID-TA11253 Expected publication date: TBC
In development Reference number: GID-TA11690 Expected publication date: TBC
In development Reference number: GID-TA11663 Expected publication date: TBC
Discontinued Reference number: GID-TAG360
In development Reference number: GID-TA11021 Expected publication date: TBC
In development Reference number: GID-TA11401 Expected publication date: TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]
In development Reference number: GID-TA11505 Expected publication date: TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
In development Reference number: GID-TA11368 Expected publication date: TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
In development Reference number: GID-TA11265 Expected publication date: TBC
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.
View recommendations for PH51Show all sections
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.